Placental Decidual Arteriopathy and Vascular Endothelial Growth Factor A Expression Among Women With or Without Human Immunodeficiency Virus.
Africa
Malperfusion
histology
immunohistochemistry
intra-uterine growth restriction
pathology
pregnancy
pregnant
resource-limited
small for gestational age
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
08 12 2021
08 12 2021
Historique:
pubmed:
22
4
2021
medline:
13
1
2022
entrez:
21
4
2021
Statut:
ppublish
Résumé
Women with human immunodeficiency virus (HIV) (WHIV) are at higher risk of adverse birth outcomes. Proposed mechanisms for the increased risk include placental arteriopathy (vasculopathy) and maternal vascular malperfusion (MVM) due to antiretroviral therapy and medical comorbid conditions. However, these features and their underlying pathophysiologic mechanisms have not been well characterized in WHIV. We performed gross and histologic examination and immunohistochemistry staining for vascular endothelial growth factor A (VEGF-A), a key angiogenic factor, on placentas from women with ≥1 MVM risk factors including: weight below the fifth percentile, histologic infarct or distal villous hypoplasia, nevirapine-based antiretroviral therapy, hypertension, and preeclampsia/eclampsia during pregnancy. We compared pathologic characteristics by maternal HIV serostatus. Twenty-seven of 41 (placentas 66%) assessed for VEGF-A were from WHIV. Mean maternal age was 27 years. Among WHIV, median CD4 T-cell count was 440/µL, and the HIV viral load was undetectable in 74%. Of VEGF-A-stained placentas, both decidua and villous endothelium tissue layers were present in 36 (88%). VEGF-A was detected in 31 of 36 (86%) with decidua present, and 39 of 40 (98%) with villous endothelium present. There were no differences in VEGF-A presence in any tissue type by maternal HIV serostatus (P = .28 to >.99). MVM was more common in placentas selected for VEGF-A staining (51 vs 8%; P < .001). VEGF-A immunostaining was highly prevalent, and staining patterns did not differ by maternal HIV serostatus among those with MVM risk factors, indicating that the role of VEGF-A in placental vasculopathy may not differ by maternal HIV serostatus.
Sections du résumé
BACKGROUND
Women with human immunodeficiency virus (HIV) (WHIV) are at higher risk of adverse birth outcomes. Proposed mechanisms for the increased risk include placental arteriopathy (vasculopathy) and maternal vascular malperfusion (MVM) due to antiretroviral therapy and medical comorbid conditions. However, these features and their underlying pathophysiologic mechanisms have not been well characterized in WHIV.
METHODS
We performed gross and histologic examination and immunohistochemistry staining for vascular endothelial growth factor A (VEGF-A), a key angiogenic factor, on placentas from women with ≥1 MVM risk factors including: weight below the fifth percentile, histologic infarct or distal villous hypoplasia, nevirapine-based antiretroviral therapy, hypertension, and preeclampsia/eclampsia during pregnancy. We compared pathologic characteristics by maternal HIV serostatus.
RESULTS
Twenty-seven of 41 (placentas 66%) assessed for VEGF-A were from WHIV. Mean maternal age was 27 years. Among WHIV, median CD4 T-cell count was 440/µL, and the HIV viral load was undetectable in 74%. Of VEGF-A-stained placentas, both decidua and villous endothelium tissue layers were present in 36 (88%). VEGF-A was detected in 31 of 36 (86%) with decidua present, and 39 of 40 (98%) with villous endothelium present. There were no differences in VEGF-A presence in any tissue type by maternal HIV serostatus (P = .28 to >.99). MVM was more common in placentas selected for VEGF-A staining (51 vs 8%; P < .001).
CONCLUSIONS
VEGF-A immunostaining was highly prevalent, and staining patterns did not differ by maternal HIV serostatus among those with MVM risk factors, indicating that the role of VEGF-A in placental vasculopathy may not differ by maternal HIV serostatus.
Identifiants
pubmed: 33880547
pii: 6242421
doi: 10.1093/infdis/jiab201
pmc: PMC8826031
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S694-S700Subventions
Organisme : NIAID NIH HHS
ID : K23 AI138856
Pays : United States
Organisme : NICHD NIH HHS
ID : K23 HD097300
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI141036
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Front Immunol. 2016 Jun 06;7:190
pubmed: 27375613
J Infect Dis. 2012 Dec 1;206(11):1695-705
pubmed: 23066160
Placenta. 2017 Apr;52:106-113
pubmed: 28454692
Lancet Infect Dis. 2012 Apr;12(4):330-40
pubmed: 22364680
Obstet Gynecol. 2017 Nov;130(5):1112-1120
pubmed: 29016509
Placenta. 2019 Nov;87:16-22
pubmed: 31525711
J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):94-102
pubmed: 30272633
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Pediatr Dev Pathol. 2017 Jan-Feb;20(1):44-48
pubmed: 28276297
Am J Obstet Gynecol. 2017 Dec;217(6):684.e1-684.e17
pubmed: 29031892
Acta Obstet Gynecol Scand. 2019 Dec;98(12):1585-1594
pubmed: 31370094
J Obstet Gynaecol Res. 2020 Mar;46(3):369-375
pubmed: 32003128
Placenta. 2016 Jun;42:37-43
pubmed: 27238712
BMJ Open. 2019 Aug 5;9(8):e027344
pubmed: 31383698
Am J Clin Pathol. 2020 Jul 7;154(2):225-235
pubmed: 32338725
Trop Med Int Health. 2017 May;22(5):604-613
pubmed: 28214384
Arch Pathol Lab Med. 1994 Jul;118(7):698-701
pubmed: 8024402
Bull Exp Biol Med. 2006 Feb;141(2):216-8
pubmed: 16984100
Arch Pathol Lab Med. 2016 Jul;140(7):698-713
pubmed: 27223167
J Clin Invest. 2003 Mar;111(5):649-58
pubmed: 12618519
Arch Gynecol Obstet. 2019 Dec;300(6):1583-1589
pubmed: 31667612
APMIS. 2018 Jul;126(7):551-560
pubmed: 30129127
J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):320-324
pubmed: 33060419
Biomed Res Int. 2014;2014:982159
pubmed: 24959596
J Clin Endocrinol Metab. 2006 Jan;91(1):180-4
pubmed: 16263826
Pregnancy Hypertens. 2016 Oct;6(4):418-422
pubmed: 27939493